# Toward site-specific characterization of structural perturbations on glycosylated Fc using NMR at natural abundance

**Authors:** Béatrice Vibert, Sarah Nguyen, Faustine Henot, Camille Doyen, Oscar Hernandez-Alba, Sarah Cianférani, Séverine Clavier, Oriane Frances, Jérôme Boisbouvier

PMC · DOI: 10.1007/s10858-025-00484-9 · Journal of Biomolecular Nmr · 2026-02-17

## TL;DR

This paper introduces a new NMR method to detect structural changes in therapeutic antibodies without isotopic labeling, improving quality control.

## Contribution

The study provides the first comprehensive methyl resonance assignment for a glycosylated Fc fragment of an IgG1 antibody.

## Key findings

- 94% of methyl resonances were assigned for a non-glycosylated Fc fragment using cell-free expression and NMR.
- 83% assignment coverage was achieved for a glycosylated Fc fragment derived from a CHO-produced antibody.
- The assignment enabled atomic-level analysis of methionine oxidation effects on Fc structure.

## Abstract

Monoclonal antibodies (mAbs) are leading therapeutic agents due to their high specificity and limited side effects. Ensuring their structural integrity under stress and maintaining batch consistency require robust quality control. Methyl 2D NMR has emerged as a powerful tool to probe mAb structure at natural isotopic abundance, enabling spectral fingerprint comparisons across production batches to detect subtle structural changes. However, extracting atomic-level structural information requires assignment of methyl resonances to their amino acids. While such assignments are available for several antigen-binding fragments (Fabs), no comprehensive assignment has been reported for the crystallisable fragment (Fc). In this study, we present the methyl group assignment of the 50-kDa Fc fragment of an immunoglobulin G1 (IgG1) antibody. Using cell-free expression, strategic isotopic labelling, and high-quality 2D and 3D NMR experiments, we successfully assigned 94% of methyl resonances of a non-glycosylated Fc. Given that therapeutic mAbs are typically produced in Chinese Hamster Ovary (CHO) cells, we transferred this assignment to the methyl spectrum of a glycosylated Fc fragment obtained by the enzymatic cleavage of a CHO-produced mAb at natural abundance, achieving 83% assignment coverage. This assignment was then used to investigate the impact of methionine oxidation on Fc structure at atomic resolution using NMR. The methyl group assignment transforms 2D methyl NMR fingerprinting into a powerful tool for quality control. It enables the direct comparison of spectra acquired on mAbs produced at natural abundance, allowing the detection and localisation of chemical modifications and structural changes without the need for isotopic labelling. This approach offers a robust solution for monitoring the structural integrity of therapeutic antibodies throughout development and manufacturing.

The online version contains supplementary material available at 10.1007/s10858-025-00484-9.

## Linked entities

- **Proteins:** Ighg1 (immunoglobulin heavy constant gamma 1 (G1m marker)), fc (flecking), FANCB (FA complementation group B)

## Full-text entities

- **Genes:** disulfide bond isomerase [NCBI Gene 13905684], LAMP1 [NCBI Gene 100689406]
- **Diseases:** complement-dependent cytotoxicity (MESH:D019966)
- **Chemicals:** spermidine (MESH:D013095), acetic acid (MESH:D019342), tryptophan (MESH:D014364), ipilimumab (MESH:D000074324), PBS (MESH:D007854), DTT (MESH:D004229), 13C (MESH:C000615229), Thr (MESH:D013912), glycine (MESH:D005998), cyclic AMP (MESH:D000242), magnesium (MESH:D008274), asparagine (MESH:D001216), Val (MESH:D014633), adalimumab (MESH:D000068879), IPTG (MESH:D007544), D2O (MESH:D017666), alpha-ketoisocaproic acid (MESH:C013082), Leu (MESH:D007930), ampicillin (MESH:D000667), amide (MESH:D000577), H2O (MESH:D014867), TB (MESH:D013725), folinic acid (MESH:D002955), ammonium acetate (MESH:C018824), U- (MESH:D014501), cysteine (MESH:D003545), EDTA (MESH:D004492), Ile (MESH:D007532), amino acid (MESH:D000596), tBHP (MESH:D020122), Glycans (MESH:D011134), carbon (MESH:D002244), creatine phosphate (MESH:D010725), GlcNAc (MESH:D000117), Ala (MESH:D000409), oxidized glutathione (MESH:D019803), trastuzumab (MESH:D000068878), NaCl (MESH:D012965), Met (MESH:D008715), 2H (MESH:D003903), CSP (-), glycerol (MESH:D005990), disulfide (MESH:D004220), Betaine (MESH:D001622), HEPES (MESH:D006531), sodium phosphate (MESH:C018279)
- **Species:** Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Homo sapiens (human, species) [taxon 9606], Escherichia coli (E. coli, species) [taxon 562], Escherichia coli BL21(DE3) (strain) [taxon 469008]
- **Cell lines:** CHO — Cricetulus griseus (Chinese hamster), Spontaneously immortalized cell line (CVCL_0213), S30 — Rattus norvegicus (Rat), Rat hepatocellular carcinoma, Cancer cell line (CVCL_1949), -28a — Oryctolagus cuniculus (Rabbit), Transformed cell line (CVCL_6E94), TOP10 — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_TT29)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12913268/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12913268/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC12913268/full.md

---
Source: https://tomesphere.com/paper/PMC12913268